Christine Joy Rico Erb, NP
Nurse Practitioner · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 3
Offices
3 locations · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Christine Joy Rico Erb’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence C17100 · Cancelled
Licence status: Cancelled · since 1955 · University of Cincinnati College of Medicine.
License has been voluntarily canceled, or the license has been expired for at least five years and has not been renewed. No practice is permitted.
Matched on the licence number without its letter prefix; check the name before relying on it.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$90,378
Medicare paid this office $90,378 for 612 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 288 | $30,977 | $94 |
| Long return visit (40+ min) | 162 | $22,933 | $131 |
| Short return visit (20+ min) | 175 | $11,876 | $65 |
| Insertion of lower leg neurostimulator electrode | 13 | $9,936 | $97 |
| Ultrasound measurement of bladder capacity after voiding | 298 | $4,252 | $11 |
See all 7 services
| Return visit (30+ min) | 288 | $30,977 | $94 |
| Long return visit (40+ min) | 162 | $22,933 | $131 |
| Short return visit (20+ min) | 175 | $11,876 | $65 |
| Insertion of lower leg neurostimulator electrode | 13 | $9,936 | $97 |
| Ultrasound measurement of bladder capacity after voiding | 298 | $4,252 | $11 |
| Simple insertion of temporary bladder tube | 26 | $3,992 | $52 |
| Simple bladder irrigation and/or instillation | 22 | $1,924 | $66 |
Who their Medicare patients are
612 Original Medicare patients in 2024. Average age 76 · Under 65 3% · 85 and older 15% · Women 35% · Also on Medicaid 15% · Health risk score 1.43. Above the middle of the specialty; the typical nurse practitioner clinician is at 1.42.
Conditions among them: High blood pressure 75% · Chronic kidney disease 35% · Coronary heart disease 31% · Diabetes 30% · Cancer 23% · Atrial fibrillation 22% · Depression 20% · Heart failure 16% · COPD 12% · Dementia 10% · Stroke 10%.
The office billed $550,919, Medicare allowed $124,515 and paid $90,378; for 3,134 services of 22 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 612 | 3,134 | 76 | 1.43 | $550,919 | $90,378 |
| 2023 | 482 | 1,425 | 76 | 1.39 | $537,763 | $97,714 |
| 2022 | 375 | 1,260 | 77 | 1.42 | $521,331 | $95,570 |
| 2021 | 243 | 799 | 76 | 1.50 | $399,810 | $75,074 |
| 2020 | 174 | 563 | 76 | 1.57 | $259,047 | $40,335 |
| 2019 | 111 | 163 | 74 | 1.56 | $72,442 | $12,413 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 8 services
| Long return visit (40+ min) | 248 | $38,523 | $129 |
| Insertion of lower leg neurostimulator electrode | 37 | $26,051 | $99 |
| Return visit (30+ min) | 173 | $18,804 | $94 |
| Ultrasound measurement of bladder capacity after voiding | 287 | $4,129 | $11 |
| Short return visit (20+ min) | 56 | $3,850 | $64 |
| Telehealth originating site facility fee | 87 | $1,953 | $21 |
| Simple insertion of temporary bladder tube | 15 | $1,372 | $51 |
| Urinalysis, manual test | 40 | $140 | $3 |
2022: 8 services
| Insertion of lower leg neurostimulator electrode | 41 | $37,138 | $100 |
| Long return visit (40+ min) | 182 | $29,015 | $135 |
| Return visit (30+ min) | 96 | $10,180 | $93 |
| Short return visit (20+ min) | 55 | $4,086 | $72 |
| Ultrasound measurement of bladder capacity after voiding | 192 | $2,853 | $11 |
| Simple insertion of temporary bladder tube | 18 | $2,026 | $52 |
| Telehealth originating site facility fee | 54 | $1,153 | $21 |
| Urinalysis, manual test | 26 | $89 | $3 |
2021: 8 services
| Insertion of lower leg neurostimulator electrode | 38 | $36,900 | $109 |
| Long return visit (40+ min) | 100 | $16,370 | $139 |
| Return visit (30+ min) | 72 | $8,122 | $98 |
| Short return visit (20+ min) | 45 | $3,089 | $66 |
| Simple insertion of temporary bladder tube | 17 | $2,292 | $52 |
| Telehealth originating site facility fee | 49 | $1,025 | $19 |
| Short return visit | 19 | $840 | $42 |
| Urinalysis, manual test | 11 | $52 | $3 |
2020: 6 services
| Insertion of lower leg neurostimulator electrode | 29 | $23,464 | $105 |
| Short return visit (20+ min) | 105 | $6,582 | $51 |
| Telephone medical discussion with physician, 21-30 minutes | 16 | $1,496 | $88 |
| Return visit (30+ min) | 20 | $1,349 | $61 |
| Telehealth originating site facility fee | 50 | $1,151 | $21 |
| Short return visit | 22 | $835 | $38 |
2019: 3 services
| Short return visit (20+ min) | 79 | $5,029 | $58 |
| Insertion of lower leg neurostimulator electrode | 20 | $4,632 | $110 |
| Return visit (30+ min) | 15 | $1,293 | $86 |
Drugs they prescribed that Part D paid
$287,402
Pharmacies billed $287,402 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
1,472 generic and 297 brand-name prescriptions · $287,402 in drug cost · 209 antibiotic prescriptions to 129 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Myrbetriq | 178 | $167,692 | $942 |
| Gemtesa | 86 | $74,758 | $869 |
| Tamsulosin | 585 | $11,515 | $20 |
| Finasteride | 405 | $5,577 | $14 |
| Trospium Chloride | 81 | $5,321 | $66 |
See all 16 drugs
| Myrbetriq | 178 | $167,692 | $942 |
| Gemtesa | 86 | $74,758 | $869 |
| Tamsulosin | 585 | $11,515 | $20 |
| Finasteride | 405 | $5,577 | $14 |
| Trospium Chloride | 81 | $5,321 | $66 |
| Silodosin | 30 | $3,635 | $121 |
| Estradiol | 32 | $1,981 | $62 |
| Tadalafil | 15 | $1,540 | $103 |
| Dutasteride | 21 | $1,372 | $65 |
| Alfuzosin Hcl Er | 34 | $866 | $25 |
| Nitrofurantoin Mono-Macro | 66 | $788 | $12 |
| Cephalexin | 48 | $289 | $6 |
| Ciprofloxacin | 33 | $177 | $5 |
| Sulfamethoxazole-Trimethoprim | 42 | $159 | $4 |
| Ampicillin Trihydrate | 14 | $157 | $11 |
| Doxazosin Mesylate | 11 | $126 | $11 |
Year by year
| 2024 | 1,769 | 514 | None | 17% | $287,402 |
| 2023 | 1,381 | 419 | None | 15% | $203,070 |
| 2022 | 1,143 | 363 | 0% (0) | 16% | $174,884 |
| 2021 | 1,009 | 277 | 0% (0) | 12% | $121,051 |
| 2020 | 695 | 198 | None | 20% | $128,900 |
| 2019 | 182 | 90 | None | 18% | $27,375 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 14 drugs
| Myrbetriq | 160 | $146,254 | $914 |
| Tamsulosin | 458 | $14,614 | $32 |
| Gemtesa | 14 | $6,926 | $495 |
| Silodosin | 36 | $6,343 | $176 |
| Trospium Chloride | 89 | $5,772 | $65 |
| Finasteride | 263 | $5,358 | $20 |
| Estradiol | 34 | $3,224 | $95 |
| Tadalafil | 13 | $2,720 | $209 |
| Dutasteride | 24 | $1,841 | $77 |
| Alfuzosin Hcl Er | 23 | $915 | $40 |
| Nitrofurantoin Mono-Macro | 42 | $641 | $15 |
| Cephalexin | 74 | $463 | $6 |
| Ciprofloxacin | 33 | $245 | $7 |
| Sulfamethoxazole-Trimethoprim | 36 | $155 | $4 |
2022: 17 drugs
| Myrbetriq | 153 | $136,049 | $889 |
| Tamsulosin | 372 | $9,748 | $26 |
| Finasteride | 190 | $4,076 | $21 |
| Tadalafil | 26 | $3,996 | $154 |
| Estradiol | 29 | $2,597 | $90 |
| Trospium Chloride | 40 | $2,456 | $61 |
| Silodosin | 20 | $2,391 | $120 |
| Potassium Citrate Er | 11 | $1,671 | $152 |
| Oxybutynin Chloride Er | 16 | $1,295 | $81 |
| Dutasteride | 13 | $1,293 | $99 |
| Nitrofurantoin Mono-Macro | 39 | $958 | $25 |
| Alfuzosin Hcl Er | 18 | $637 | $35 |
| Doxazosin Mesylate | 14 | $463 | $33 |
| Amitriptyline | 14 | $438 | $31 |
| Cephalexin | 41 | $282 | $7 |
| Ciprofloxacin | 33 | $181 | $5 |
| Sulfamethoxazole-Trimethoprim | 32 | $93 | $3 |
2021: 18 drugs
| Myrbetriq | 95 | $81,228 | $855 |
| Tamsulosin | 311 | $8,935 | $29 |
| Tadalafil | 22 | $4,108 | $187 |
| Finasteride | 167 | $3,896 | $23 |
| Oxybutynin Chloride Er | 56 | $2,933 | $52 |
| Methenamine Hippurate | 13 | $2,377 | $183 |
| Trospium Chloride | 19 | $2,199 | $116 |
| Potassium Citrate Er | 11 | $1,515 | $138 |
| Silodosin | 12 | $1,415 | $118 |
| Estradiol | 13 | $1,279 | $98 |
| Nitrofurantoin Mono-Macro | 42 | $786 | $19 |
| Dutasteride | 14 | $605 | $43 |
| Alfuzosin Hcl Er | 23 | $599 | $26 |
| Terazosin | 17 | $434 | $26 |
| Cephalexin | 40 | $229 | $6 |
| Ampicillin Trihydrate | 16 | $213 | $13 |
| Sulfamethoxazole-Trimethoprim | 36 | $161 | $4 |
| Ciprofloxacin | 23 | $64 | $3 |
2020: 13 drugs
| Myrbetriq | 112 | $86,235 | $770 |
| Tamsulosin | 198 | $4,616 | $23 |
| Oxybutynin Chloride Er | 54 | $3,420 | $63 |
| Trospium Chloride | 19 | $3,073 | $162 |
| Finasteride | 87 | $2,147 | $25 |
| Tadalafil | 11 | $1,888 | $172 |
| Estradiol | 12 | $1,567 | $131 |
| Alfuzosin Hcl Er | 15 | $428 | $29 |
| Nitrofurantoin Mono-Macro | 20 | $360 | $18 |
| Oxybutynin Chloride | 16 | $259 | $16 |
| Terazosin | 11 | $188 | $17 |
| Cephalexin | 24 | $101 | $4 |
| Sulfamethoxazole-Trimethoprim | 20 | $73 | $4 |
2019: 4 drugs
| Myrbetriq | 26 | $15,215 | $585 |
| Oxybutynin Chloride Er | 25 | $1,456 | $58 |
| Tamsulosin | 37 | $700 | $19 |
| Finasteride | 19 | $423 | $22 |
Money from drug and device companies
$1,736 in 2025
| 2025 | 4 | 21 | None | $1,736 |
| 2024 | 4 | 4 | None | $123 |
| 2023 | 1 | 1 | None | $87 |
| 2022 | 1 | 1 | None | $57 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Medtronic | Interstim | $1,205 | 14 payments
|
| Sumitomo Pharma America | Gemtesa | $293 | 4 payments
|
| Urogen Pharma | Zusduri | $217 | 2 payments
|
| Boston Scientific | Bulkamid | $20 | 1 payment
|
See all 21 published payments
| Sumitomo Pharma America | Meals · 2025-12-17 | Gemtesa | $125 |
| Urogen Pharma | Meals · 2025-12-01 | Zusduri | $34 |
| Medtronic | Meals · 2025-11-14 | Interstim | $113 |
| Sumitomo Pharma America | Meals · 2025-11-05 | None | $32 |
| Sumitomo Pharma America | Meals · 2025-11-05 | Gemtesa | $107 |
| Urogen Pharma | Meals · 2025-11-03 | Zusduri | $183 |
| Sumitomo Pharma America | Meals · 2025-09-26 | Gemtesa | $29 |
| Boston Scientific | Meals · 2025-06-03 | Bulkamid | $20 |
| Medtronic | Meals · 2025-04-14 | Interstim | $11 |
| Medtronic | Education · 2025-04-04 | Interstim | $36 |
| Medtronic | Meals · 2025-04-04 | Interstim | $70 |
| Medtronic | Meals · 2025-04-04 | Interstim | $67 |
| Medtronic | Meals · 2025-04-04 | Interstim | $16 |
| Medtronic | Meals · 2025-04-04 | Interstim | $31 |
| Medtronic | Meals · 2025-04-04 | Interstim | $5 |
| Medtronic | Travel · 2025-04-03 | Interstim | $289 |
| Medtronic | Travel · 2025-04-03 | Interstim | $54 |
| Medtronic | Travel · 2025-04-03 | Interstim | $239 |
| Medtronic | Travel · 2025-04-03 | Interstim | $72 |
| Medtronic | Meals · 2025-04-03 | Interstim | $141 |
| Medtronic | Meals · 2025-02-14 | Interstim | $61 |
See earlier years (2024, 2023, 2022)
2024: $123
| Boston Scientific | Ams 700 | $43 | 1 payment
|
| Bioprotect Medical | Bioprotect Balloon Implant System | $39 | 1 payment
|
| Sumitomo Pharma America | Gemtesa | $20 | 1 payment
|
| Medtronic | Interstim | $20 | 1 payment
|
2023: $87
| Sumitomo Pharma America | Gemtesa | $87 | 1 payment
|
2022: $57
| Bayer HealthCare Pharmaceuticals | Nubeqa | $57 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1508025628
- Licence
- CA 17100California C17100: Cancelled
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Nurse practitioner (363L00000X); Federal specialty code 363LA2200X (363LA2200X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2008-06-04
- NPI last updated
- 2025-12-30
- NPI record certified
- 2025-12-30
This is when the NPI record was last certified, not a medical board exam.